BiotechTube

Vevye® + Xiidra®

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

Jul 9, 2025 → Apr 30, 2026

NCT ID
NCT07025811

About Vevye® + Xiidra®

Vevye® + Xiidra® is a approved stage product being developed by Roche for Dry Eye Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07025811. Target conditions include Dry Eye Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT07025811ApprovedRecruiting

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
49
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
47
atomoxetine + Matching PlaceboEli LillyPhase 2
52
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
18
EvolocumabHeartFlowApproved
80
High intensity lipid loweringHeartFlowPre-clinical
18
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
72
LanifibranorInventivaPhase 2
47
LY450139 + PlaceboEli LillyPhase 3
77
Dulaglutide + PlaceboEli LillyPhase 3
77
raloxifene + placeboEli LillyPhase 3
77
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
47
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77

Other Products from Roche

EmicizumabApproved
85
rituximab + methotrexate + methylprednisolone + acetaminophen + antihistamineApproved
85
RituximabApproved
85
mycophenolate mofetil [CellCept]Approved
85
saquinavir/ritonavir + atazanavir/ritonavirApproved
85